SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Shares surged roughly 9% to record highs, with traders celebrating AMD crossing a $1 trillion market cap for the first time amid a broad semiconductor rally tied to a server-CPU demand narrative and reports of upcoming chip price increases. Reaction is split: bulls hail the milestone and pricing power, while bears dismiss the move as a short-squeeze/FOMO-driven pump at stretched valuations and warn of a pullback.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is sliding sharply after its Capital Markets Day, where management laid out long-term blockbuster-launch and pipeline targets that failed to reassure investors worried about Eli Lilly competition and the looming semaglutide patent cliff. The community is heavily criticizing CEO Mike Doustdar's communication and strategy, while dip buyers argue the selloff is an overreaction on an already cheap valuation.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

CRML is surging after Trump announced a U.S.-Denmark-Greenland security agreement granting Washington permanent security control of Greenland and barring adversarial investment, refocusing attention on the company's Tanbreez rare earth project. Trader sentiment is heavily bullish with widespread short-squeeze speculation, though some in the community caution that a security-only pact preserving Danish sovereignty and Greenland's mining rightsand not yet formally signeddoes little to change the company's fundamentals.

Maase, Inc. operates as a integrated provider and operator of artificial intelligence (AI) centric full-scene digital systems. The firm focus on areas of flexible energy deployment and intelligent commercial network operation, and provide closed-loop solutions from computing infrastructure, smart hardware and full-scene services, aiming to achieve large-scale implementation of AI technologies across industries. The company was founded by Hai Feng Yu on August 6, 2018 and is headquartered in Qingdao, China.

Maase Inc. - Ordinary Shares - Class A

Highest Performances Holdings Inc. - ADR

A rapid cadence of enterprise AI contract announcements  spanning multi-month compute-capacity leases and prepaid token-based API agreements  is dominating the discussion, with many traders framing it as a shift from one-off projects toward recurring revenue, alongside attention on the company's newly published AI security white paper. Reaction is split: bulls see the stock as undervalued on the contract flow and volume-backed chart action, while skeptics note the price has slipped despite the news and question margins, cash conversion, and potential dilution from a shelf registration.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is rallying on the AI CPU-demand narrative, with traders amplifying management's comment that the company can meet only about half of customer CPU demand and speculating that agentic AI workloads like Meta's Muse model require far more CPUs per GPU, while reported exploratory talks over SK Hynix using Intel's Ohio fab capacity for memory production add fuel. Bulls frame the move as a short squeeze powered by heavy call buying, while skeptics call it an overextended momentum rally for a still money-losing company with no fresh company-specific news.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp Nasdaq-100 rally toward record territory is dominating the conversation, with traders citing sliding crude oil on hopes of U.S.-Iran de-escalation, easing Treasury yields, and AI/semiconductor strength as drivers, while many question what news is behind the move given the Fed's hawkish rate hike, elevated yields, and record diesel prices. Reaction is split between call buyers celebrating a melt-up toward new highs and skeptics calling it an unsustainable, manipulated-looking pump or bull trap, with some traders speculating the run is election-driven ahead of the Trump-Xi summit.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Reports that Paramount Skydance is in advanced settlement talks with California's attorney general over the state antitrust suit blocking its Warner Bros. Discovery merger are driving attention, with a proposed California production investment and studio- and CNN-related concessions reportedly under discussion. Traders largely view a settlement as clearing the path to closing before a looming daily ticking fee, though some cite conflicting reports on the talks' progress, oppose conditions like keeping the studios separate, and suspect heavy short-selling is suppressing the stock.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros is trending amid a persistent slide to 52-week lows, with the community split between bulls calling the drop an overdone valuation reset for a company still posting strong growth and store expansion, and bears citing its elevated multiple, dilution fears tied to a shelf registration, insider selling, and competition from 7 Brew. The failed Salad and Go acquisition bid  abandoned after being outbid, with a break-up fee retained  remains a recurring focal point in the debate.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

Traders are focused on the Federal Reserve's rate hike and what it means for SoFi's rate-sensitive lending business, with bulls arguing the move was already baked into guidance and bears warning of higher funding costs and refinancing headwinds. The debate is amplified by ongoing frustration over SoFi's underperformance versus fintech peers like Robinhood and disagreement over whether the reported Citizens Bank employee-poaching lawsuit is a genuine threat or a legal scare tactic.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm is rallying sharply alongside the broader chip complex as traders embrace a server-CPU demand narrative for agentic AI workloads, reinforced by CEO Rene Haas's comments that demand has never been stronger, supply constraints are easing, and multiyear deals are converting a large AGI CPU pipeline into revenue. Bulls tout a rotation from memory into CPU names, while skeptics argue the move reflects a sector-wide bid rather than fresh news and warn the stock's valuation is stretched.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates

Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of -104.76% and +5.01%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Agenus (AGEN) Earnings Expected to Grow: Should You Buy?

Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tarsus Pharmaceuticals, Inc. (TARS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Tarsus Pharmaceuticals (TARS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

All You Need to Know About Tarsus Pharmaceuticals (TARS) Rating Upgrade to Buy

Tarsus Pharmaceuticals (TARS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Tarsus Pharmaceuticals (TARS) Moves 7.5% Higher: Will This Strength Last?

Tarsus Pharmaceuticals (TARS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme

Equity

Culper’s central allegation is that Tarsus has driven XDEMVY uptake among Medicare patients by funding copay assistance. 


Tarsus Pharmaceuticals Stock Drops as Short Seller Alleges Illegal Copay Scheme

Tarsus Pharmaceuticals Inc (NASDAQ:TARS) shares are falling Wednesday. Short-seller Culper Research published a report Wednesday alleging the company's sole commercial product relies on an illegal Medicare copay scheme. Here's what you should know.read more...

Ultragenyx (RARE) Soars 5.2%: Is Further Upside Left in the Stock?

Ultragenyx (RARE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Biogen (BIIB) Moves 7.0% Higher: Will This Strength Last?

Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Noteworthy Friday Option Activity: TARS, LYV, RIOT

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Tarsus Pharmaceuticals Inc (Symbol: TARS), where a total volume of 3,560 contracts has been traded thus far today, a contract volume which is representative of a...

Tarsus Pharmaceuticals, Inc. is a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Tarsus Pharmaceuticals Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$1.46	--	--	N/A
Q2 '26	-$0.19	-$0.43	-124.22%	MISSED
Q1 '26	-$0.40	-$0.16	60.03%	BEAT
Q4 '25	-$0.09	-$0.20	-115.11%	MISSED
Q3 '25	-$0.35	-$0.30	14.14%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

TARS Earnings

Upcoming Earnings: Q3 '26

Historical Earnings